PDE2A Blocking Peptide for STJ502249 peptide (STJ505269)
SPECIFICATIONS
ImmunogenSynthetic peptide corresponding to unique N-terminal amino acid sequence on PDE2A gene.
General Information
| Short Description | PDE2A Blocking Peptide for STJ502249 is synthetically produced from the N-Term sequence and is suitable for use in western blot applications. |
| Applications | Immunodepletion/Immunocompetition |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Formulation | Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction | Store at-20ยฐC for long term storage. Avoid freeze-thaw cycles. |
Target Information
| Immunogen | Synthetic peptide corresponding to unique N-terminal amino acid sequence on PDE2A gene. |
| Immunogen Region | N-Term |
| Specificity | This blocking peptide is recommended for use in combination with PDE2A antibody, STJ502249 |
Additional Info
| Background | Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. May play a role in fat metabolism. Regulates cAMP binding of RAPGEF3. Through simultaneous binding to RAPGEF3 and PIK3R6 assembles a signaling complex in which the PI3K gamma complex is activated by RAPGEF3 and which is involved in angiogenesis. |
Information sourced from Uniprot.org